0.87
+0.0069(+0.80%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
9
First IPO Date
May 25, 2018
| Name | Title | Pay | Year Born |
| Mr. Corey N. Fishman | President, Chief Executive Officer & Director | 1.13M | 1965 |
| Dr. Michael W. Dunne M.D. | Strategic Advisor & Director | 135,000 | 1960 |
| Ms. Judith M. Matthews | Chief Financial Officer | 677,035 | 1971 |
| Dr. Steven I. Aronin M.D. | Senior Vice President & Head of Clinical Development | 0 | N/A |
| Mr. Tom Loughman Ph.D. | Senior Vice President of Technical Operations | 0 | N/A |
| Ms. Louise Barrett | Senior Vice President of Legal Affairs & Secretary | 0 | N/A |
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.